Brigatinib for ALK-positive crizotinib resistant non-small cell lung cancer

Share This Post

Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncology (ASCO) in Chicago on June 6, 2016 local time: the first report An important randomized phase II clinical trial of the efficacy and safety of using Brigatinib (BRG) in patients with ALK + crizotinib-resistant non-small cell lung cancer (NSCLC).

BRG is an oral tyrosine kinase inhibitor (TKI) in the observation period. It has preclinical activity against ALK rearrangements and CRZ-resistant mutations. This clinical phase 1/2 trial shows good prospects for BRG. Both BRG’s response rate and AEs can vary with the starting dose, therefore, in this ongoing randomized study, two BRG use options were evaluated.

The results of this study show that BRG has a clear response to treatment, stable PFS, and acceptable safety characteristics. Therefore, they plan to conduct a phase III clinical trial comparing CRZ BRG 90 mg qd * 7 days and 180 mg qd in patients with ALK + advanced NSCLC and CRZ in patients who have not used TKI.

In this trial, patients ≥ 18 years of age, ALK + NSCLC progressed after using CRZ and no other ALK TKI patients were available. According to whether the patient has a baseline condition of intracranial metastasis and the best response to the previous use of CRZ, the patients were randomly divided into 1: 1 oral BRG 90 mg qd (group A) or 90 mg qd x 7d and 180 mg qd (B group).

The primary endpoint is observation-assessment-confirmation of ORR per RECIST v1.1. Key secondary endpoints include PFS and IRC to assess formal ORR and CNS responses. 222 patients were randomly divided into A / B group, n = 112 / n = 110. As of September 21, 2015, the last patient was included. The average age was 51/57 years old, and 71% / 67% had brain metastases.

The proportion of patients in groups A and B was 63% / 74% while the experiment was still in progress on December 7, 2015, and the average duration of treatment was 25 weeks / 23 weeks. Observation-assessment of group A: 46% of confirmed ORR (39 confirmed reactions + 12 single responses waiting to be confirmed), including 1 confirmed complete response (CRs); ORR of group B: 54% (49 confirmed reactions) + 10 responses awaiting confirmation), including 5 confirmed CRs. The median PFS for A / B is 8.8 months / 11.1 months.

Toxic events in group A / B were 44/25, the most common emergency treatment AEs of grade ≥ 3, group A / B included: increased CPK (3% / 8%), hypertension (4% / 5%), Lung infection (3% / 5%), rash (1% / 4%), elevated blood lipids (3% / 2%) and pneumonia (2% / 3%). In 6% of patients, pulmonary events occurred at an early stage (3% ≥ grade 3 within 7 days of initiation of treatment); this event was not seen in group B and increased to 180 mg within 7 days of initiation of treatment and thereafter. The interruption and reduction of A / B group due to AEs were 3% / 6% and 7% / 18%, respectively.

Website |  + posts

Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.

Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.

Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.

Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.

These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.

Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor
Cancer

Vimseltinib is approved by the USFDA for symptomatic tenosynovial giant cell tumor

The FDA approved vimseltinib for symptomatic tenosynovial giant cell tumor (TGCT) in patients who cannot be treated with surgery. The oral CSF1R inhibitor blocks tumor growth and alleviates symptoms, providing a surgery-free way to control TGCT. The approval is based on clinical trial evidence of substantial tumor shrinkage and symptom relief. The approval is a significant step forward in TGCT treatment, enhancing the quality of life for these patients.

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
Blood cancer

Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma

The FDA approved brentuximab vedotin in combination with lenalidomide and rituximab to treat relapsed or refractory large B-cell lymphoma (LBCL). The combination represents a new option for treatment after failure of initial therapies. The approval follows the presentation of data from clinical trials showing that this combination improved patient outcomes. This combination is a new strategy in the management of LBCL and provides a greater number of available treatments for those with few choices.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟